Literature DB >> 11510798

Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.

R Trisolini1, L Lazzari Agli, D Tassinari, D Rondelli, A Cancellieri, M Patelli, F Falcone, V Poletti.   

Abstract

Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma. The findings from transbronchial lung biopsy and bronchoalveolar lavage (BAL) were consistent with an organizing diffuse alveolar damage pattern. Once extensive microbiological studies proved negative, corticosteroids were given and a complete remission of clinical and radiological abnormalities was achieved. It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11510798

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  27 in total

1.  Pulmonary toxicity of 5-fluoracil and oxaliplatin.

Authors:  A Ruiz-Casado; M D García; M A Racionero
Journal:  Clin Transl Oncol       Date:  2006-08       Impact factor: 3.405

Review 2.  Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: a review.

Authors:  Gunther Klautke; Rainer Fietkau
Journal:  Int J Colorectal Dis       Date:  2006-10-28       Impact factor: 2.571

3.  Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer.

Authors:  Xavier Hernández Yagüe; Ester Soy; Bernardo Queralt Merino; Josep Puig; Miguel Beltrán Fabregat; Ramón Colomer
Journal:  Clin Transl Oncol       Date:  2005-12       Impact factor: 3.405

4.  Drug-associated acute lung injury: a population-based cohort study.

Authors:  Rajanigandha Dhokarh; Guangxi Li; Christopher N Schmickl; Rahul Kashyap; Jyoti Assudani; Andrew H Limper; Ognjen Gajic
Journal:  Chest       Date:  2012-10       Impact factor: 9.410

5.  Interstitial lung disease associated with oxaliplatin: description of two cases.

Authors:  C Pena Alvarez; H J Suh Oh; A Sáenz de Miera Rodríguez; F R García Arroyo; M Covela Rúa; L Salgado Boquete; P M López Clemente; M Constenla Figueiras
Journal:  Clin Transl Oncol       Date:  2009-05       Impact factor: 3.405

6.  An oral fluoropyrimidine agent S-1 induced interstitial lung disease: A case report.

Authors:  Hiromichi Yamane; Masahide Kinugawa; Shigeki Umemura; Yasuhiro Shiote; Kenichiro Kudo; Toshimitsu Suwaki; Haruhito Kamei; Nagio Takigawa; Katsuyuki Kiura
Journal:  World J Clin Oncol       Date:  2011-07-10

7.  S-1-induced lung injury combined with pneumocystis pneumonia.

Authors:  Shuichi Yano
Journal:  BMJ Case Rep       Date:  2013-02-04

8.  Interstitial pneumonia arising in a patient treated with oxaliplatin, 5-fluorouracil, and, leucovorin (FOLFOX).

Authors:  Katsuki Muneoka; Yoshio Shirai; Masataka Sasaki; Toshifumi Wakai; Jun Sakata; Katsuyoshi Hatakeyama
Journal:  Int J Clin Oncol       Date:  2009-10-25       Impact factor: 3.402

9.  Role of (18)F-FDG PET-CT in Monitoring the Cyclophosphamide Induced Pulmonary Toxicity in Patients with Breast Cancer - 2 Case Reports.

Authors:  Sameer Kamalakar Taywade; Rakesh Kumar; Sainath Bhethanabhotla; Chandrasekhar Bal
Journal:  Nucl Med Mol Imaging       Date:  2015-12-22

10.  Fatal pneumonitis induced by oxaliplatin.

Authors:  Sara Arévalo Lobera; Naiara Sagastibeltza Mariñelarena; Ibone Elejoste Echeberría; Mireia Melé Olivé; Larraitz Egaña Otaño; Laura Basterretxea Badiola; Adelaida La Casta Muñoa; Mikel Azkue Gabilondo
Journal:  Clin Transl Oncol       Date:  2008-11       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.